Global Markets Direct's, 'Diabetic Macular Edema - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Diabetic Macular Edema, complete with latest updates, and special features on late-stage and discontinued projects. https://www.reportscorner.com/reports/15422/Diabetic-Macular-Edema---Pipeline-Review,-H1-2013/

1. RC
Reports Corner
Diabetic Macular Edema - Pipeline Review, H1
2013

2. DescriptionDescription
Reports Cornerwww.reportscorner.com
Global Markets Direct's, 'Diabetic Macular Edema - Pipeline
Review, H1 2013', provides an overview of the indication's
therapeutic pipeline. This report provides information on the
therapeutic development for Diabetic Macular Edema, complete
with latest updates, and special features on late-stage and
discontinued projects.

3. Brief SummaryBrief Summary
Reports Cornerwww.reportscorner.com
"Global Markets Direct's, 'Diabetic Macular Edema - Pipeline
Review, H1 2013', provides an overview of the indication's
therapeutic pipeline. This report provides information on the
therapeutic development for Diabetic Macular Edema, complete
with latest updates, and special features on late-stage and
discontinued projects. It also reviews key players involved in the
therapeutic development for Diabetic Macular Edema. Diabetic
Macular Edema - Pipeline Review, Half Year is built using data and
information sourced from Global Markets Direct's proprietary
databases, Company/University websites, SEC filings, investor
presentations and featured press releases from
company/university sites and industry-specific third party
sources, put together by Global Markets Direct's team.Note*:
Certain sections in the report may be removed or altered based on
the availability and relevance of data for the indicated disease.

4. Brief SummaryBrief Summary
Reports Cornerwww.reportscorner.com
Scope- A snapshot of the global therapeutic scenario for Diabetic
Macular Edema.- A review of the Diabetic Macular Edema
products under development by companies and
universities/research institutes based on information derived from
company and industry-specific sources.- Coverage of products
based on various stages of development ranging from discovery
till registration stages.- A feature on pipeline projects on the basis
of monotherapy and combined therapeutics.- Coverage of the
Diabetic Macular Edema pipeline on the basis of route of
administration and molecule type.- Key discontinued pipeline
projects.- Latest news and deals relating to the products.Reasons
to buy- Identify and understand important and diverse types of
therapeutics under development for Diabetic Macular Edema.-
Identify emerging players with potentially strong product portfolio
and design effective counter-strategies to gain competitive
advantage.-

5. Brief SummaryBrief Summary
Reports Cornerwww.reportscorner.com
Plan mergers and acquisitions effectively by identifying players of
the most promising pipeline.- Devise corrective measures for
pipeline projects by understanding Diabetic Macular Edema
pipeline depth and focus of Indication therapeutics.- Develop and
design in-licensing and out-licensing strategies by identifying
prospective partners with the most attractive projects to enhance
and expand business potential and scope.- Modify the therapeutic
portfolio by identifying discontinued projects and understanding
the factors that drove them from pipeline."

6. Table of ContentsTable of Contents
Reports Cornerwww.reportscorner.com
Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Diabetic Macular Edema Overview 9
Therapeutics Development 10
An Overview of Pipeline Products for Diabetic Macular Edema 10
Diabetic Macular Edema Therapeutics under Development by Companies 12
Diabetic Macular Edema Therapeutics under Investigation by Universities/Institutes 15
Late Stage Products 16
Comparative Analysis 16
Mid Clinical Stage Products 17

7. Table of ContentsTable of Contents
Reports Cornerwww.reportscorner.com
Comparative Analysis 17
Early Clinical Stage Products 18
Comparative Analysis 18
Discovery and Pre-Clinical Stage Products 19
Comparative Analysis 19
Diabetic Macular Edema Therapeutics - Products under Development by Companies 20
Diabetic Macular Edema Therapeutics - Products under Investigation by Universities/Institutes 22
Companies Involved in Diabetic Macular Edema Therapeutics Development 23
F. Hoffmann-La Roche Ltd. 23
Allergan, Inc. 24
pSivida Corp. 25
Eli Lilly and Company 26
GlaxoSmithKline plc 27
Quark Pharmaceuticals, Inc. 28
Santen Pharmaceutical Co., Ltd. 29

8. Table of ContentsTable of Contents
Reports Cornerwww.reportscorner.com
Lux Biosciences, Inc. 30
Novagali Pharma SA 31
Astellas Pharma Inc. 32
iCo Therapeutics Inc. 33
Mesoblast Ltd 34
NicOx SA 35
SANWA KAGAKU KENKYUSHO CO.,LTD. 36
Regeneron Pharmaceuticals, Inc. 37
ThromboGenics NV 38
Foamix Ltd. 39
Molecular Partners AG 40
Aciont Inc. 41
Charlesson LLC. 42
Icon Bioscience, Inc. 43
Eleven Biotherapeutics 44

9. Table of ContentsTable of Contents
Reports Cornerwww.reportscorner.com
Ampio Pharmaceuticals, Inc. 45
Diabetic Macular Edema - Therapeutics Assessment 46
Assessment by Monotherapy Products 46
Assessment by Route of Administration 47
Assessment by Molecule Type 49
Drug Profiles 52
ranibizumab - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
darapladib - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
iCo-007 - Drug Profile 57

10. Table of ContentsTable of Contents
Reports Cornerwww.reportscorner.com
Product Description 57
Mechanism of Action 57
R&D Progress 57
dexamethasone acetate - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
ocriplasmin - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
Eylea - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64

11. Table of ContentsTable of Contents
Reports Cornerwww.reportscorner.com
dexamethasone dipropionate - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
Drug For Diabetic Macular Edema - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
dexamethasone acetate - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
PF-655 - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70

12. Table of ContentsTable of Contents
Reports Cornerwww.reportscorner.com
fluocinolone acetonide - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
CLT-003 - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
betamethasone - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
danazol - Drug Profile 76
Product Description 76
Mechanism of Action 76

13. Table of ContentsTable of Contents
Reports Cornerwww.reportscorner.com
R&D Progress 76
MP-0112 - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
ruboxistaurin - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
sirolimus - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
minocycline - Drug Profile 83
Product Description 83

14. Table of ContentsTable of Contents
Reports Cornerwww.reportscorner.com
Mechanism of Action 83
R&D Progress 83
AKB-9778 - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
KH-902 - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
LX-213 - Drug Profile 89
Product Description 89
Mechanism of Action 89
R&D Progress 89
Mesenchymal Precursor Cells For Diabetic Macular Edema - Drug Profile 90

15. Table of ContentsTable of Contents
Reports Cornerwww.reportscorner.com
Product Description 90
Mechanism of Action 90
R&D Progress 90
NCX-422 - Drug Profile 91
Product Description 91
Mechanism of Action 91
R&D Progress 91
ALG-1001 - Drug Profile 92
Product Description 92
Mechanism of Action 92
R&D Progress 92
Steroid For Diabetic Macular Edema - Drug Profile 94
Product Description 94
Mechanism of Action 94
R&D Progress 94

16. Table of ContentsTable of Contents
Reports Cornerwww.reportscorner.com
Plasma Kallikrein Inhibitors Programme - Drug Profile 95
Product Description 95
Mechanism of Action 95
R&D Progress 95
Plasma Kallikrein Inhibitors Programme - Drug Profile 97
Product Description 97
Mechanism of Action 97
R&D Progress 97
Plasma Kallikrein Inhibitors Oral Programme - Drug Profile 98
Product Description 98
Mechanism of Action 98
R&D Progress 98
EBI-018 - Drug Profile 99
Product Description 99
Mechanism of Action 99

17. Table of ContentsTable of Contents
www.reportscorner.com
R&D Progress 99
Vascular Adhesion Protein-1 Inhibitor - Drug Profile 100
Product Description 100
Mechanism of Action 100
R&D Progress 100
Diabetic Macular Edema Therapeutics - Drug Profile Updates 101
Diabetic Macular Edema Therapeutics - Discontinued Products 123
Diabetic Macular Edema Therapeutics - Dormant Products 124
Diabetic Macular Edema - Product Development Milestones 126
Featured News & Press Releases 126
Oct 05, 2012: NICE Publishes Draft Guidance On Novartis's Ranibizumab For Diabetic Macular Edema
After Rapid Review 126
Sep 19, 2012: Aerpio Therapeutics Initiates Phase Ib/IIa Trial Of AKB-9778 In Diabetic Macular Edema 127
Sep 05, 2012: NICE Accepts Alimera Sciences's Iluvien Subgroup Data For Review 127
Aug 10, 2012: FDA Approves Lucentis For Treatment Of Diabetic Macular Edema 128
Aug 08, 2012: NICE Turns Down Alimera's Iluvien For Treatment Of Diabetic Macular Edema 130

18. Table of ContentsTable of Contents
www.reportscorner.com
Aug 01, 2012: Ampio Announces Successful Pre-IND Meeting With Ophthalmology Division Of FDA On
Optina For Treatment Of Diabetic Macular Edema 131
Aug 01, 2012: pSivida Reports Alimera's Intention To Resubmit Application To FDA For ILUVIEN In DME
Using Data From Completed Trials 132
Jul 26, 2012: Alimera Sciences's ILUVIEN Receives Marketing Authorization In Germany For Treatment Of
Chronic Diabetic Macular Edema 132
Jul 26, 2012: FDA Advisory Committee Recommends Approval Of Roche's Lucentis For Treatment Of
Diabetic Macular Edema 133
Jul 24, 2012: FDA Reviews Lucentis Ahead Of Panel Vote 134
Appendix 135
Methodology 135
Coverage 135
Secondary Research 135
Primary Research 135
Expert Panel Validation 135
Contact Us 136
Disclaimer 13
R&D Progress 70

19. For more informationFor more information
Reports Cornerwww.reportscorner.com
For more information please visit our website
https://www.reportscorner.com/reports/15422/Diabetic-Macular-Edema---Pipeline-
Review,-H1-2013/

20. Reports Corner
Thank YouThank You
www.reportscorner.com
RC
Contact us: contact@reportscorner.com